-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] On August 5, a large number of listed pharmaceutical companies issued announcements, involving matters such as over-evaluation, increase or decrease in holdings, and resignati.
The author briefly sorted out important announcements for industry reference on.
[Overview] Shanghai Pharmaceuticals announced that the folic acid tablets (5mg) of its holding subsidiary Changzhou Pharmaceutical Factory passed the consistency evaluation of generic dru.
The drug is mainly used for folic acid deficiency caused by various reasons, megaloblastic anemia caused by folic acid deficiency and folic acid deficiency caused by chronic hemolytic anem.
For women who are planning pregnancy and known to be at risk, it can prevent fetal neural tube defec.
As of the date of this announcement, the company has invested approximately RMB 5,893,500 in research and development expenses for the consistency evaluation of the dr.
Zhejiang Pharmaceutical issued an announcement saying that the company's "Approval Notice for Supplementary Drug Application" for Ciprofloxacin Hydrochloride Tablets (25g) had been review.
The drug is a third-generation quinolone antibacterial drug, suitable for the treatment of lower respiratory tract infection caused by Gram-negative bacteria in adults, bronchopulmonary infection in cystic fibrosis or bronchiectasis, pneumonia, chronic suppurative otitis media, urinary tract infection infections, complicated urinary tract infections,e.
Up to now, the company has invested about 67 million yuan in research and development expenses for the consistency evaluation of ciprofloxacin hydrochloride table.
[Increase and decrease holdings] SINBON Pharma issued a shareholding increase announceme.
As of August 3, 2022, .
Gao Wenlin, a senior executive of the company, has completed more than half of the increase in shareholding pl.
During the period of August 3, 2008, the company increased its holdings of 1,018,700 shares through the centralized bidding transaction of the Shenzhen Stock Exchange trading system, accounting for 05% of the company's total share capital, and the cumulative amount of increased holdings was 5,008,100 yu.
Tailin Bio issued a share reduction announceme.
Ye Xingyue, the board secretary and chief financial officer who holds 32% of the shares, plans to reduce the shareholding by centralized bidding within six months after the announcement of the pre-disclosure of the shareholding pl.
The company's shares do not exceed 65,600 shares, accounting for 0789% of the company's total share capit.
[Acceptance] According to the announcement of Xianju Pharmaceutical, the company recently received the notice of acceptance of the domestically produced drug registration of progesterone vaginal sustained-release gel issued by the State Food and Drug Administrati.
The drug is indicated for assisted reproductive technolo.
The developer Columbia's progesterone vaginal extended-release gel was approved for import registration in China in 2008 for the supplemental treatment of progesterone in assisted reproductive technolo.
Currently, the twenty-seventh batch of generic drug reference preparations is recommended as a reference preparati.
The specifications of the progesterone vaginal sustained-release gel declared by the company this time are consistent with the specifications of the original research that have been approved for marketing, and are declared according to 4 categories of chemica.
[Resignation] Asia Pacific Pharmaceuticals announced that the company's board of supervisors received a written resignation report submitted by Xu Da on August 4, 202 He applied for his resignation as a supervisor of the company due to personal reaso.
After resignation, Xu Da will no longer hold any positions in the compa.
As of the date of this announcement, Xu Da did not hold any shares of the compa.
[Equity Transaction] Hainan Haiyao announced that the company intends to transfer 43% of the equity of Shanghai Lishengte, its holding subsidia.
The purpose of this sale is to accelerate the development of Shanghai Lisound, introduce new investors, promote Shanghai Lisound's reform and innovation, stimulate vitality, and create better conditions for its market expansion and business development in the field of medical devices; In order to optimize the company's asset structure, withdraw funds to support the company's drug research and development and sal.
Proton shares issued an announcement that the company plans to use its own funds to repurchase some of the company's public shares in a centralized bidding transaction for the implementation of equity incentives or employee stock ownership pla.
The proposed repurchase amount is not less than 50 million yuan (inclusive) and not more than 100 million yuan (inclusive), and the repurchase price does not exceed 85 yuan per share (inclusiv.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
The author briefly sorted out important announcements for industry reference on.
[Overview] Shanghai Pharmaceuticals announced that the folic acid tablets (5mg) of its holding subsidiary Changzhou Pharmaceutical Factory passed the consistency evaluation of generic dru.
The drug is mainly used for folic acid deficiency caused by various reasons, megaloblastic anemia caused by folic acid deficiency and folic acid deficiency caused by chronic hemolytic anem.
For women who are planning pregnancy and known to be at risk, it can prevent fetal neural tube defec.
As of the date of this announcement, the company has invested approximately RMB 5,893,500 in research and development expenses for the consistency evaluation of the dr.
Zhejiang Pharmaceutical issued an announcement saying that the company's "Approval Notice for Supplementary Drug Application" for Ciprofloxacin Hydrochloride Tablets (25g) had been review.
The drug is a third-generation quinolone antibacterial drug, suitable for the treatment of lower respiratory tract infection caused by Gram-negative bacteria in adults, bronchopulmonary infection in cystic fibrosis or bronchiectasis, pneumonia, chronic suppurative otitis media, urinary tract infection infections, complicated urinary tract infections,e.
Up to now, the company has invested about 67 million yuan in research and development expenses for the consistency evaluation of ciprofloxacin hydrochloride table.
[Increase and decrease holdings] SINBON Pharma issued a shareholding increase announceme.
As of August 3, 2022, .
Gao Wenlin, a senior executive of the company, has completed more than half of the increase in shareholding pl.
During the period of August 3, 2008, the company increased its holdings of 1,018,700 shares through the centralized bidding transaction of the Shenzhen Stock Exchange trading system, accounting for 05% of the company's total share capital, and the cumulative amount of increased holdings was 5,008,100 yu.
Tailin Bio issued a share reduction announceme.
Ye Xingyue, the board secretary and chief financial officer who holds 32% of the shares, plans to reduce the shareholding by centralized bidding within six months after the announcement of the pre-disclosure of the shareholding pl.
The company's shares do not exceed 65,600 shares, accounting for 0789% of the company's total share capit.
[Acceptance] According to the announcement of Xianju Pharmaceutical, the company recently received the notice of acceptance of the domestically produced drug registration of progesterone vaginal sustained-release gel issued by the State Food and Drug Administrati.
The drug is indicated for assisted reproductive technolo.
The developer Columbia's progesterone vaginal extended-release gel was approved for import registration in China in 2008 for the supplemental treatment of progesterone in assisted reproductive technolo.
Currently, the twenty-seventh batch of generic drug reference preparations is recommended as a reference preparati.
The specifications of the progesterone vaginal sustained-release gel declared by the company this time are consistent with the specifications of the original research that have been approved for marketing, and are declared according to 4 categories of chemica.
[Resignation] Asia Pacific Pharmaceuticals announced that the company's board of supervisors received a written resignation report submitted by Xu Da on August 4, 202 He applied for his resignation as a supervisor of the company due to personal reaso.
After resignation, Xu Da will no longer hold any positions in the compa.
As of the date of this announcement, Xu Da did not hold any shares of the compa.
[Equity Transaction] Hainan Haiyao announced that the company intends to transfer 43% of the equity of Shanghai Lishengte, its holding subsidia.
The purpose of this sale is to accelerate the development of Shanghai Lisound, introduce new investors, promote Shanghai Lisound's reform and innovation, stimulate vitality, and create better conditions for its market expansion and business development in the field of medical devices; In order to optimize the company's asset structure, withdraw funds to support the company's drug research and development and sal.
Proton shares issued an announcement that the company plans to use its own funds to repurchase some of the company's public shares in a centralized bidding transaction for the implementation of equity incentives or employee stock ownership pla.
The proposed repurchase amount is not less than 50 million yuan (inclusive) and not more than 100 million yuan (inclusive), and the repurchase price does not exceed 85 yuan per share (inclusiv.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
